Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
Evogene partnered with Tel Aviv University's Blavatnik Center for Drug Discovery to launch a joint initiative aimed at accelerating AI-driven small-molecule drug discovery. The collaboration combines Evogene's ChemPass AI computational engine with BCDD's experimental infrastructure to support academic entrepreneurs in translating novel disease targets into viable drug candidates.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.